First United Bank & Trust Has $2.85 Million Stock Holdings in Danaher Co. (NYSE:DHR)

First United Bank & Trust reduced its position in shares of Danaher Co. (NYSE:DHR) by 1.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,418 shares of the conglomerate’s stock after selling 142 shares during the period. Danaher comprises 1.0% of First United Bank & Trust’s investment portfolio, making the stock its 27th largest holding. First United Bank & Trust’s holdings in Danaher were worth $2,851,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Decker Retirement Planning Inc. bought a new stake in Danaher during the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher in the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher in the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in Danaher during the 3rd quarter valued at approximately $55,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR opened at $238.41 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s fifty day moving average price is $234.85 and its two-hundred day moving average price is $253.51. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The company has a market capitalization of $172.20 billion, a price-to-earnings ratio of 45.50, a P/E/G ratio of 4.30 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.02 earnings per share. As a group, analysts anticipate that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of analyst reports. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Guggenheim initiated coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective on the stock. Scotiabank began coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price for the company. KeyCorp lifted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Stephens reissued an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.